EFNB1水平决定了独特的药物反应模式,指导了B细胞瘤的精密治疗
Xiaoxi Li1, Chenxiao Zhang1, Minyao Deng1
1Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
iScience
|December 29, 2023
概括
EFNB1水平预测B细胞瘤的药物反应和预后. 这种生物标志物可以通过分层患者和指示细胞分化来指导精确治疗,从而改善治疗策略.
科学领域:
- 分子瘤学分子瘤学
- 生物标志物发现发现
- 精准医学是一门精准的医学.
背景情况:
- 多omics数据推进了B细胞瘤诊断.
- 缺乏预测性生物标志物阻碍了精准治疗.
- 在B细胞恶性瘤中EFNB1的作用尚未得到充分研究.
研究的目的:
- 为了确定B细胞瘤精度治疗的预测生物标志物.
- 研究EFNB1在药物反应和患者预后中的作用.
- 开发一种基于EFNB1.1的B细胞恶性瘤分层模型.
主要方法:
- 对公开可用的多主题数据的分析.
- 在B细胞瘤细胞系中评估EFNB1水平.
- 对EFNB1与药物反应,酸化信号和源细胞 (COO) 评分的相关性分析.
主要成果:
- 在具有不同EFNB1水平的细胞系中观察到明显的药物反应模式.
- EFNB1过度表达增强了SRC和STMN1酸化,增加了对SRC抑制剂和细胞毒药物的敏感性.
- EFNB1水平与GCB-DLBCL患者的预后以及COO分数相关,表明其在细胞分化中的作用.
结论:
- EFNB1是一种有前途的生物标志物,用于预测B细胞瘤中药物反应.
- EFNB1水平可以对针对性治疗的患者进行分层,并表明细胞分化.
- EFNB1与预后有关,可以指导B细胞恶性瘤的精准医学策略.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


